The filing adds little beyond what investors already knew. HCA explicitly says its second-quarter results and updated outlook were consistent with the July 14 preview, making this release primarily a formal confirmation rather than a fresh surprise. The published consensus was roughly $7.56 of adjusted EPS, versus $7.59 reported, while revenue was $20.23 billion versus estimates around $19.76 billion.
| Metric | Q2 2026 | Q2 2025 | Read-through |
|---|---|---|---|
| Revenue | $20.230B | $18.605B | +8.7% (Financial Highlights) |
| Adjusted EPS | $7.59 | $6.84 | +11.0% (Supplemental Non-GAAP Disclosures) |
| Adjusted EBITDA | $4.027B | $3.849B | +4.6%; margin fell to 19.9% from 20.7% (Supplemental Non-GAAP Disclosures) |
| Same-facility equivalent admissions | +2.7% | — | Volume growth (Operating Statistics) |
| Operating cash flow | $2.335B | $4.210B | Down sharply year over year (Balance Sheet and Cash Flows from Operations) |
Underlying demand was solid, but the earnings quality was mixed. Same-facility admissions and equivalent admissions grew 2.5% and 2.7%, respectively, while emergency-room visits rose 3.6%. However, inpatient surgeries declined 2.3% and outpatient surgeries fell 3.4%, pointing to a less favorable service mix. Adjusted EBITDA grew only 4.6% against 8.7% revenue growth, and the margin compressed by 80 basis points (Operating Statistics; Supplemental Non-GAAP Disclosures).
Public-policy effects are doing much of the work—and masking pressure elsewhere. HCA recorded roughly $400 million of incremental net benefit from Medicaid supplemental payments, primarily tied to Florida, while estimating that the shift toward uninsured patients reduced pretax income by roughly $400 million in the quarter. The Florida program also included $980 million of revenue and $557 million of related expense from periods before 2026, so the headline revenue growth is not entirely representative of recurring operating momentum (Second Quarter Commentary).
The full-year outlook remains materially below the original plan, but that downgrade was already disclosed. Compared with January guidance, the revised ranges reduce EPS to $28.70–$30.50 from $29.10–$31.50, adjusted EBITDA to $15.4–$16.1 billion from $15.55–$16.45 billion, and net income to $6.3–$6.7 billion from $6.495–$7.035 billion. HCA also increased its estimated exchange-related headwind to $1.0–$1.2 billion, partly offset by a revised $300–$500 million benefit from Medicaid programs (2026 Updated Guidance and Key Assumptions). Because those changes were announced on July 14, the July 24 filing does not newly worsen expectations.
Net read: confirmation, not a fresh beat. The quarter modestly exceeded published EPS and revenue benchmarks, but the result was previewed, profitability was pressured by payer and service mix, cash generation weakened, and the lower annual outlook was already in the market. That makes the appropriate scorecard “In line” for this filing rather than a new positive surprise.
Read the original 8-K on SEC EDGAR ↗